Skip to main content

Table 4 Comparing occurrences of hematological and non-hematological AEs between the propensity score matched treatment groups

From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Treatment comparison Platinum/Pemetrexed vs. Platinum/Docetaxel    Platinum/Pemetrexed vs. Platinum/Paclitaxel    Platinum/Pemetrexed vs. Platinum/Gemcitabine    Platinum/Pemetrexed vs. Platinum/Vinorelbine   
Matched pairs 95 RR P value* 118 RR P value* 199 RR P value* 72 RR P value*
All grades AE N % N %    N % N %    N % N %    N % N %   
Hematological AE                         
Leukopenia 29 30.5% 27 28.4% 1.074 0.752 34 28.8% 39 33.1% 0.872 0.508 64 32.2% 84 42.2% 0.762 0.041 18 25.0% 27 37.5% 0.667 0.106
Neutropenia 24 25.3% 19 20.0% 1.263 0.336 29 24.6% 35 29.7% 0.829 0.396 63 31.7% 57 28.6% 1.105 0.540 12 16.7% 23 31.9% 0.522 0.034
Thrombocytopenia 24 25.3% 24 25.3% 1.000 1.000 32 27.1% 34 28.8% 0.941 0.773 59 29.6% 100 50.3% 0.590 <0.001 25 34.7% 26 36.1% 0.962 0.876
Anemia 34 35.8% 31 32.6% 1.097 0.647 46 39.0% 53 44.9% 0.868 0.370 87 43.7% 125 62.8% 0.696 <0.001 35 48.6% 46 63.9% 0.761 0.063
Any hematological AE 56 58.9% 58 61.1% 0.966 0.752 70 59.3% 80 67.8% 0.875 0.189 130 65.3% 163 81.9% 0.798 <0.001 47 65.3% 58 80.6% 0.810 0.056
Non-hematological AE                     0.0%   0.0%   
Alopecia 3 3.2% 15 15.8% 0.200 0.005 1 0.8% 8 6.8% 0.125 0.020 2 1.0% 18 9.0% 0.111 <0.001 0 0.0% 1 1.4% 0.000 1.000
Arthralgia 5 5.3% 4 4.2% 1.250 0.706 0 0.0% 0 0.0% 2 1.0% 8 4.0% 0.250 0.058 0 0.0% 0 0.0%
Cough 1 1.1% 2 2.1% 0.500 0.564 1 0.8% 1 0.8% 1.000 1.000 3 1.5% 12 6.0% 0.250 0.020 2 2.8% 1 1.4% 2.000 0.564
Dermatitis 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Diarrhea 1 1.1% 2 2.1% 0.500 0.317 1 0.8% 0 0.0% 1.000 3 1.5% 0 0.0% 0.250 2 2.8% 3 4.2% 0.667 0.655
Dyspnea 1 1.1% 0 0.0% 1.000 1 0.8% 0 0.0% 1.000 3 1.5% 6 3.0% 0.500 0.317 1 1.4% 0 0.0% 1.000
Edema 1 1.1% 0 0.0% 1.000 1 0.8% 0 0.0% 1.000 3 1.5% 1 0.5% 3.000 0.317 1 1.4% 0 0.0% 1.000
Fatigue 11 11.6% 11 11.6% 1.000 1.000 10 8.5% 27 22.9% 0.370 0.001 18 9.0% 62 31.2% 0.290 <0.001 13 18.1% 23 31.9% 0.565 0.048
Nausea 63 66.3% 67 70.5% 0.940 0.527 78 66.1% 84 71.2% 0.929 0.446 134 67.3% 148 74.4% 0.905 0.122 53 73.6% 53 73.6% 1.000 1.000
Peripheral neuropathy 1 1.1% 3 3.2% 0.333 0.317 0 0.0% 5 4.2% 0.000 0.063 3 1.5% 2 1.0% 1.500 0.657 1 1.4% 2 2.8% 0.500 0.564
Rash 2 2.1% 0 0.0% 0.500 2 1.7% 0 0.0% 0.500 5 2.5% 5 2.5% 1.000 1.000 1 1.4% 0 0.0% 1.000
Stomatitis 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 1 0.5% 0.000 1.000 0 0.0% 2 2.8% 0.000 0.500
Vomiting 40 42.1% 47 49.5% 0.851 0.286 51 43.2% 52 44.1% 0.981 0.895 92 46.2% 94 47.2% 0.979 0.849 31 43.1% 37 51.4% 0.838 0.366
Weight loss 0 0.0% 1 1.1% 0.000 1.000 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
  1. AE, adverse event; RR, rate ratio. *P values less than 0.05 were in bold to indicate significant differences.